Prospects for productivity

Nature Reviews Drug Discovery

Volumn 3, Issue 5, 2004, Pages 451-456

  Booth, Bruce ^a   Zemmel, Rodney ^a  

^a MCKINSEY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ANTIBIOTIC AGENT; ANTIMIGRAINE AGENT; ATORVASTATIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BEVACIZUMAB; BORTEZOMIB; CASPOFUNGIN; CETUXIMAB; CORTICOSTEROID DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DROTRECOGIN; FLUOROURACIL; FOLINIC ACID; MEVINOLIN; NEUROLEPTIC AGENT; OMEPRAZOLE; OXALIPLATIN; SEROTONIN UPTAKE INHIBITOR; ZILEUTON;

ARTICLE; ASTHMA; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; DRUG LABELING; DRUG MARKETING; DRUG RESEARCH; DRUG SYNTHESIS; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HUMAN; INVESTMENT; MYCOSIS; PATIENT MONITORING; PHARMACOGENOMICS; PRIORITY JOURNAL; PROFIT; RISK BENEFIT ANALYSIS; SEPSIS; STOMACH ULCER;

EID: 2442465034     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1384     Document Type: Article

References (15)

1. Grabowski, H. G. Public policy and pharmaceutical innovation. Health Care Financ. Rev. 4, 75-87 (1982).
2. Fruits of Genomics (Lehman Brothers, New York, 2001).
3. Edmunds, R. et al. Splicing a cost squeeze into the genomics revolution. Mckinsey Quarterly 2, 15-18 (2001).
4. Hopkins, A. & Groom, C. The druggable genome. Nature Rev. Drug Discov. 1, 727-730 (2002).
5. Ma, P. & Zemmel, R. Value of novelty? Nature Rev. Drug Discov. 1, 571-672 (2002).
6. Booth, B. & Zemmel, R. Quest for the best. Nature Rev. Drug Discov. 2, 838-841 (2003).
7. Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3-25 (1997).
8. Wenlock, M. C., Austin, R. P., Barton, P., Davis, A. M. & Leeson, P. D. A comparison of physiochemical property profiles of development and marketed oral drugs. J. Med. Chem. 46, 1250-1256 (2003).
9. Vieth, M. et al. Characteristic physical properties and structural fragments of marketed oral drugs. J. Med. Chem. 47, 224-232 (2004).
10. Sneader, W. Drug Prototypes and their Exploitation (John Wiley & Sons, Chichester, 1996).
11. Ostholm, I. Drug Discovery: A Pharmacist's Story (Swedish Pharmaceutical, Stockholm, 1995).
12. Horrobin, D. F. Innovation in pharmaceuticals. J. R. Soc. Med. 93, 341-345 (2000).
13. Horrobin, D. F. Modern biomedical research: an internally self-consistent universe with little contact with medical reality. Nature Rev. Drug Discov. 2, 151-154 (2003).
14. Erickson, D. Wanted: drug hunters. In Vivo 45, (2003).
15. Reichert, J. M. & Paquette, C. Therapeutic recombinant proteins: trends in US approvals 1982 to 2002. Curr. Opin. Mol. Ther. 5, 139-147 (2003).